Feasibility of the Use of Weighted Blankets to Improve Sleep Among Patients with Hematological Malignancies
Not Applicable
Not yet recruiting
- Conditions
- Hematological Malignancies
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2024-09-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06584955
Evaluating Mechanical Properties of Post-Mastectomy Skin Flaps to Estimate Reconstruction Risks, the EMPOWER Study
Recruiting
- Conditions
- Breast Carcinoma
- Interventions
- Other: Non-Interventional Study
- First Posted Date
- 2024-09-04
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 110
- Registration Number
- NCT06584396
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
Phase 1
Recruiting
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 128
- Registration Number
- NCT06576037
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT06575374
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Phase II Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT06569368
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
Phase 2
Recruiting
- Conditions
- Myelodysplastic SyndromesChronic Myelomonocytic LeukemiaClonal Cytopenia of Undetermined Significance
- Interventions
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT06566742
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT06567314
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT06563375
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT06563505
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT06561087
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath